Alembic Pharmaceuticals 将来の成長

Future 基準チェック /46

Alembic Pharmaceuticals利益と収益がそれぞれ年間21.5%と11%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.9% 22%なると予測されています。

主要情報

21.5%

収益成長率

22.0%

EPS成長率

Pharmaceuticals 収益成長	17.6%
収益成長率	11.0%
将来の株主資本利益率	15.9%
アナリストカバレッジ	Good
最終更新日	11 Nov 2024

今後の成長に関する最新情報

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Nov 10

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Recent updates

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Nov 10

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Sep 25

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Sep 03

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Jul 20

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

業績と収益の成長予測

NSEI:APLLTD - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	83,261	10,620	6,129	9,777	9
3/31/2026	74,913	8,293	5,344	8,107	11
3/31/2025	66,964	6,442	3,907	8,161	11
9/30/2024	63,573	6,468	811	4,092	N/A
6/30/2024	63,042	6,299	N/A	N/A	N/A
3/31/2024	62,286	6,158	4,757	8,032	N/A
12/31/2023	61,181	5,902	N/A	N/A	N/A
9/30/2023	59,966	5,317	2,042	6,027	N/A
6/30/2023	58,766	5,285	N/A	N/A	N/A
3/31/2023	56,526	3,420	2,805	7,240	N/A
12/31/2022	56,619	2,113	N/A	N/A	N/A
9/30/2022	54,246	2,662	2,893	6,751	N/A
6/30/2022	52,419	3,153	N/A	N/A	N/A
3/31/2022	53,058	5,209	1,267	5,524	N/A
12/31/2021	51,704	7,609	N/A	N/A	N/A
9/30/2021	52,131	8,771	1,767	8,309	N/A
6/30/2021	53,778	10,412	N/A	N/A	N/A
3/31/2021	53,931	11,465	8,039	14,634	N/A
12/31/2020	53,196	11,521	N/A	N/A	N/A
9/30/2020	52,144	10,937	6,209	12,378	N/A
6/30/2020	49,982	10,066	N/A	N/A	N/A
3/31/2020	46,058	8,288	-2,858	4,491	N/A
12/31/2019	43,259	7,282	N/A	N/A	N/A
9/30/2019	41,349	6,638	482	7,967	N/A
6/30/2019	40,211	6,176	N/A	N/A	N/A
3/31/2019	39,347	5,844	476	8,120	N/A
12/31/2018	38,604	5,542	N/A	N/A	N/A
9/30/2018	36,823	5,149	N/A	N/A	N/A
6/30/2018	33,445	4,364	N/A	N/A	N/A
3/31/2018	31,302	4,126	N/A	3,124	N/A
12/31/2017	29,894	4,119	N/A	N/A	N/A
9/30/2017	29,264	3,678	N/A	N/A	N/A
6/30/2017	30,165	3,661	N/A	N/A	N/A
3/31/2017	31,052	4,032	N/A	3,286	N/A
12/31/2016	30,130	3,999	N/A	N/A	N/A
9/30/2016	31,584	5,828	N/A	N/A	N/A
6/30/2016	32,942	7,515	N/A	N/A	N/A
3/31/2016	31,232	7,200	N/A	9,477	N/A
12/31/2015	30,185	6,986	N/A	N/A	N/A
9/30/2015	26,086	4,998	N/A	N/A	N/A
6/30/2015	21,469	2,881	N/A	N/A	N/A
3/31/2015	20,579	2,829	N/A	1,718	N/A
12/31/2014	20,167	2,739	N/A	N/A	N/A
9/30/2014	19,906	2,692	N/A	N/A	N/A
6/30/2014	19,303	2,535	N/A	N/A	N/A
3/31/2014	18,642	2,355	N/A	2,400	N/A

アナリストによる今後の成長予測

収入対貯蓄率: APLLTDの予測収益成長率 (年間21.5% ) は貯蓄率 ( 6.7% ) を上回っています。

収益対市場: APLLTDの収益 ( 21.5% ) はIndian市場 ( 18.1% ) よりも速いペースで成長すると予測されています。

高成長収益: APLLTDの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: APLLTDの収益 ( 11% ) Indian市場 ( 10.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: APLLTDの収益 ( 11% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: APLLTDの自己資本利益率は、3年後には低くなると予測されています ( 15.9 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/02 04:57
終値	2025/01/02 00:00
収益	2024/09/30
年間収益	2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Alembic Pharmaceuticals Limited 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。25

アナリスト	機関
Sarabjit Nangra	Angel Broking Private Limited
null null	Antique Stockbroking Ltd.
Harith Ahamed	Avendus Spark

Alembic Pharmaceuticals 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Price target increased by 7.2% to ₹1,056

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%

Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules

Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024

Now 21% overvalued after recent price rise

Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations

Investor sentiment improves as stock rises 17%

Price target increased by 7.2% to ₹1,056

Now 25% overvalued after recent price rise

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head ­ Legal

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial

Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07%

Upcoming dividend of ₹11.00 per share

Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg

Now 21% overvalued

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dividend increased to ₹11.00

Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024

Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business)

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Now 20% overvalued

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023)

Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals

Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Consensus EPS estimates fall by 19%

Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022)

Consensus EPS estimates fall by 11%

Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal